Clinical Trials & Research

Print this page SAN FRANCISCO, CA Aug 3, 2020 – Today, members of the COVID R&D Alliance AbbVie, Inc. (NYSE: ABBV), Amgen Inc. (NASDAQ: AMGN), and Takeda Pharmaceutical Co. Ltd. (NYSE: TAK) announced the first patients enrolled in the I-SPY COVID Trial (Investigation of Serial Studies to Predict Your COVID Therapeutic Response with Biomarker Integration and
0 Comments
Researchers at Ligandal Inc., the University of California San Francisco and Toyota Technological Institute at Chicago, have designed novel synthetic peptides that potently inhibit the ability of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to infect host cells. The team’s SARS-BLOCK™ peptides competitively inhibit the receptor-binding domain (RBD) on the SARS-CoV-2 spike protein – the
0 Comments
Print this page GAITHERSBURG, Md., Aug. 04, 2020 (GLOBE NEWSWIRE) – Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced Phase 1 data from its Phase 1/2 randomized, observer-blinded, placebo-controlled trial of its COVID‑19 vaccine with and without Matrix‑M™ adjuvant in healthy adults 18-59 years of age. NVX‑CoV2373, the Company’s recombinant
0 Comments
Print this page MORRISTOWN, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases through a portfolio built around gelsolin technology, announced today that it enrolled its first patient in its Phase 2 study of hospitalized patients with severe COVID-19 pneumonia. This
0 Comments
Print this page NEW BRUNSWICK, N.J., July 30, 2020 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that its lead vaccine candidate protected against infection with SARS-CoV-2, the virus that causes COVID-19, in pre-clinical studies. The data, published in Nature, show the Company’s investigational adenovirus serotype 26 (Ad26) vector-based vaccine elicited a robust immune response as
0 Comments
Print this page CAMBRIDGE, Mass., July 28, 2020 (GLOBE NEWSWIRE) – Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) today announced that its novel drug candidate, nipocalimab, has received rare pediatric disease designation from the U.S. Food and Drug Administration (FDA) for the prevention of hemolytic disease of the fetus and newborn (HDFN). Additionally, FDA granted nipocalimab orphan drug designation
0 Comments
Print this page 30 July 2020 — Nirsevimab showed a significant reduction in medically-attended lower respiratory tract infections (LRTI) and hospitalisations caused by respiratory syncytial virus (RSV) in healthy preterm infants in a positive Phase IIb trial published in the New England Journal of Medicine. The trial demonstrated for the first time that a single-dose
0 Comments
Print this page NEW YORK & MAINZ, Germany–(BUSINESS WIRE) July 27, 2020 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the start of a global (except for China) Phase 2/3 safety and efficacy clinical study to evaluate a single nucleoside-modified messenger RNA (modRNA) candidate from their BNT162 mRNA-based vaccine program against
0 Comments
Print this page Chongqing, China July 27, 2020 — Recently, National Medical Products Administration has officially released the clinical trial notification for the recombinant 2019-nCoV vaccine co-developed by Zhifei Longcom, a wholly-owned subsidiary of Zhifei, and the Institute of Microbiology of the Chinese Academy of Sciences (IMCAS). It is the first recombinant subunit 2019-nCoV vaccine
0 Comments
Print this page SAN DIEGO, CA and TAICANG, SUZHOU, China – July 20, 2020 – Connect Biopharma, a clinical-stage biopharmaceutical company focused on identifying and developing potent and specific immune modulating molecules today announced that the first patient has been dosed in a Phase 2 clinical trial of CBP-201 for the treatment of moderate-to-severe atopic
0 Comments
Print this page 20 July 2020 –  Interim results from the ongoing Phase I/II COV001 trial, led by Oxford University, showed AZD1222 was tolerated and generated robust immune responses against the SARS-CoV-2 virus in all evaluated participants. COV001 is a blinded, multi-centre, randomised controlled Phase I/II trial with 1,077 healthy adult participants, aged 18-55 years.
0 Comments
Print this page LEXINGTON, Mass.–(BUSINESS WIRE)–Jul. 7, 2020– Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases, today announced development plans to support a New Drug Application (NDA) for the novel investigational reactive aldehyde species (RASP) inhibitor
0 Comments
Reviewed by Emily Henderson, B.Sc.Jul 20 2020 Preliminary data from researchers at the University of Cincinnati Cancer Center show that immunotherapy doesn’t necessarily worsen complications for patients with both COVID-19 and cancer. This data is being presented by Layne Weatherford, PhD, UC postdoctoral fellow, at the American Association for Cancer Research Virtual Meeting: COVID-19 and
0 Comments
Print this page LA JOLLA, Calif., July 13, 2020 (GLOBE NEWSWIRE) — Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that as reported by its partner, Biocon Limited, a clinical trial conducted in India by Biocon demonstrated that itolizumab significantly reduced mortality in patients hospitalized
0 Comments
Reviewed by Emily Henderson, B.Sc.Jul 17 2020 Researchers from the Moscow Institute of Physics and Technology and their colleagues from Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry and Prokhorov General Physics Institute of the Russian Academy of Sciences have developed a breakthrough technology to resolve a key problem that has prevented the introduction of novel drugs into
0 Comments
Print this page BOSTON, July 14, 2020 (GLOBE NEWSWIRE) —  Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the first patient has been enrolled in the BOLD (Biliary atresia and the use of Odevixibat in treating Liver Disease) global Phase 3 clinical trial of odevixibat, a highly potent and selective
0 Comments
Reviewed by Emily Henderson, B.Sc.Jul 16 2020 A rapid laboratory test, the eosinophil count, readily obtained from a routine complete blood cell count (CBC) can aid in the early recognition of COVID-19 in patients, as well as provide prognostic information, according to new research in The Journal of the American Osteopathic Association. Current testing, which
0 Comments
Print this page CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jul. 14, 2020– Moderna, Inc., (Nasdaq:MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the publication of an interim analysis of the open-label Phase 1 study of mRNA-1273, its vaccine candidate against COVID-19, in The New
0 Comments
Reviewed by Emily Henderson, B.Sc.Jul 14 2020 A clever combination of soft measures can be highly effective without being as intrusive as a lockdown, finds a detailed analysis of more than 4,500 governmental measures against coronavirus spread. The study offers a ranking according to the effectiveness of single measures in reduing the reproduction number R(t)
0 Comments